161 related articles for article (PubMed ID: 34562469)
1. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
Chen F; Xu G; Tian W; Gou S
Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
[TBL] [Abstract][Full Text] [Related]
2. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
3. Circumventing drug resistance through a CK2-targeted combination via attenuating endogenous AhR-TLS-promoted genomic instability in human colorectal cancer cells.
Chen F; Wang Z; Wang Y; Gou S
Food Chem Toxicol; 2023 Jun; 176():113774. PubMed ID: 37037410
[TBL] [Abstract][Full Text] [Related]
4. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
Chen F; Pei S; Wang X; Zhu Q; Gou S
Biochem Biophys Res Commun; 2020 Jan; 521(3):753-761. PubMed ID: 31703842
[TBL] [Abstract][Full Text] [Related]
5. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
[TBL] [Abstract][Full Text] [Related]
6. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
7. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
9. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
[TBL] [Abstract][Full Text] [Related]
10. TDO2 and tryptophan metabolites promote kynurenine/AhR signals to facilitate glioma progression and immunosuppression.
Zhong C; Peng L; Tao B; Yin S; Lyu L; Ding H; Yang X; Peng T; He H; Zhou P
Am J Cancer Res; 2022; 12(6):2558-2575. PubMed ID: 35812057
[TBL] [Abstract][Full Text] [Related]
11. Blockade of chemo-resistance to 5-FU by a CK2-targeted combination via attenuating AhR-TLS-promoted genomic instability in human colon cancer cells.
Wang Z; Chen F; Wang Y; Gou S
Toxicol Appl Pharmacol; 2023 Sep; 475():116647. PubMed ID: 37543059
[TBL] [Abstract][Full Text] [Related]
12. Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1
Chen F; Zhao D; Huang Y; Wen X; Feng S
Life Sci; 2023 Dec; 335():122239. PubMed ID: 37944638
[TBL] [Abstract][Full Text] [Related]
13. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
[TBL] [Abstract][Full Text] [Related]
14. TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling.
Ding X; Jin Y; Shi X; Wang Y; Jin Z; Yin L; Gao S; Lei Y; Yang J
Biochem Pharmacol; 2024 May; 223():116172. PubMed ID: 38552852
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
[TBL] [Abstract][Full Text] [Related]
16. TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway.
Li L; Wang T; Li S; Chen Z; Wu J; Cao W; Wo Q; Qin X; Xu J
Front Oncol; 2020; 10():562823. PubMed ID: 33542896
[TBL] [Abstract][Full Text] [Related]
17. Constitutive TDO2 expression promotes liver cancer progression by an autocrine IL-6 signaling pathway.
Wu Z; Yan L; Lin J; Ke K; Yang W
Cancer Cell Int; 2021 Oct; 21(1):538. PubMed ID: 34657635
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.
Hsu YL; Hung JY; Chiang SY; Jian SF; Wu CY; Lin YS; Tsai YM; Chou SH; Tsai MJ; Kuo PL
Oncotarget; 2016 May; 7(19):27584-98. PubMed ID: 27050278
[TBL] [Abstract][Full Text] [Related]
19. Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.
Bostian AC; Eoff RL
Chem Res Toxicol; 2016 Sep; 29(9):1369-80. PubMed ID: 27482758
[TBL] [Abstract][Full Text] [Related]
20. Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.
Abuin-Martínez C; Vidal R; Gutiérrez-López MD; Pérez-Hernández M; Giménez-Gómez P; Morales-Puerto N; O'Shea E; Colado MI
Neuropharmacology; 2021 Apr; 187():108490. PubMed ID: 33607146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
